Equine Peripheral Blood-Derived Progenitors in Comparison to Bone Marrow-Derived - 《stemcells》干细胞学杂志干细胞之家



免疫细胞治疗专区	欢迎关注干细胞微信公众号

12 3 4 5 6 7 8 9 10 ... 25 下一页

返回列表

查看: 366013\|回复: 247	go Equine Peripheral Blood-Derived Progenitors in Comparison to Bone Marrow-Derived [复制链接]

江边孤钓

版主

Rank: 7 Rank: 7 Rank: 7

积分: 0
威望: 0
包包: 483

楼主

发表于 2009-3-5 00:05 |只看该作者 |倒序浏览 |打印

作者：Jens Koernera,b, Dobrila Nesica, Jose Diaz Romeroa, Walter Brehmb, Pierre Mainil-Varleta, Shawn Patrick Grogana作者单位：a Institute of Pathology, Tissue Engineering Unit, University of Bern, Bern, Switzerland;b Equine Clinic, Department of Clinical Veterinary Medicine, Vetsuisse Facilty, University of Bern, Bern, Switzerland
   ! n6 L  s( |' @+ z

      ) P' C; `7 C! F' p: K

         ! v. ~9 m  C1 }7 s

         % G' _/ @0 M3 O9 [) e3 s& q
         7 [: b) C# q% g
                  ' g* Q4 q2 u% n- w4 K8 N7 a$ Z7 A  G

      . w7 C4 b0 m2 t0 q. Q7 V1 P( I" ~

      【摘要】+ _: K$ a" N1 m, g. f& Z" g* o* e
   Fibroblast-like cells isolated from peripheral blood of human, canine, guinea pig, and rat have been demonstrated to possess the capacity to differentiate into several mesenchymal lineages. The aim of this work was to investigate the possibility of isolating pluripotent precursor cells from equine peripheral blood and compare them with equine bone marrow-derived mesenchymal stem cells. Human mesenchymal stem cells (MSCs) were used as a control for cell multipotency assessment. Venous blood (n = 33) and bone marrow (n = 5) were obtained from adult horses. Mononuclear cells were obtained by Ficoll gradient centrifugation and cultured in monolayer, and adherent fibroblast-like cells were tested for their differentiation potential. Chondrogenic differentiation was performed in serum-free medium in pellet cultures as a three-dimensional model, whereas osteogenic and adipogenic differentiation were induced in monolayer culture. Evidence for differentiation was made via biochemical, histological, and reverse transcription-polymerase chain reaction evaluations. Fibroblast-like cells were observed on day 10 in 12 out of 33 samples and were allowed to proliferate until confluence. Equine peripheral blood-derived cells had osteogenic and adipogenic differentiation capacities comparable to cells derived from bone marrow. Both cell types showed a limited capacity to produce lipid droplets compared to human MSCs. This result may be due to the assay conditions, which are established for human MSCs from bone marrow and may not be optimal for equine progenitor cells. Bone marrow-derived equine and human MSCs could be induced to develop cartilage, whereas equine peripheral blood progenitors did not show any capacity to produce cartilage at the histological level. In conclusion, equine peripheral blood-derived fibroblast-like cells can differentiate into distinct mesenchymal lineages but have less multipotency than bone marrow-derived MSCs under the conditions used in this study. 0 r) w9 `7 u8 ^- w
      【关键词】 Adult stem cells Skeleton Peripheral blood stem cells Tissue engineering
   INTRODUCTION

Isolation of mesenchymal progenitor cells has been reported from different tissues  have proven a reliable source for mesenchymal stem cells (MSCs). Preterm samples yielded successful isolation of fibroblastoid cells, whereas cell yields from full-term deliveries were inconsistent.0 o3 \5 P  `) e

Several methods have aided in the isolation and maintenance of pluripotent cells from a blood source. Density gradient techniques, such as Ficoll, have been used to separate mononuclear cells from the umbilical cord blood and peripheral blood. In addition, separation through gradient centrifugation followed by elutriation .

To enhance isolation efficiency, culture dishes have been coated with fibronectin , only sophisticated techniques have led to isolation and proliferation of fibroblastoid cells, whereas in mouse, guinea pig, and rabbit, standard isolation protocols for bone marrow-derived MSCs were used successfully.4 }1 O( o8 l& o* X2 S
) d& B. _& p$ h) w
For identification and confirmation of the mesenchymal potential, two major approaches have been described. One method is by detecting the presence of mesenchymal membrane surface markers such as CD34¨C in addition to CD105  . These studies indicate that these cells are capable of differentiating into bone and fat. However, little evidence of cartilage formation has been observed.
; S" H2 L1 I) _. ~+ ?3 |6 Q
In this study, we explored the possibility of isolating and propagating fibroblastoid cells from equine peripheral blood and subsequently provide evidence of their abilities to differentiate into aforementioned distinct mesenchymal lineages. The horse represents an animal model and also a patient, especially since its musculoskeletal system is a major part of its value in sports, breeding, and leisure activities. Peripheral blood could be a very valuable progenitor source for cell-based therapy in the treatment of tendon, ligament, and bone defects, as well as for cartilage and meniscus repair .

MATERIALS AND METHODS

ePBPs and eMSCs Isolation

Blood samples were obtained according to local animal protection guidelines from warm-blooded horses at an average age of 9.3  years. Thirty-six milliliters of fresh blood was taken from the jugular vein in four 9-ml NH4-heparin-containing tubes (Sarstedt Monovette, Nuembrecht, Germany, http://www.sarstedt.com). Samples were further processed within 1 hour. The tubes were tipped over once and placed in a rack to allow a red blood cell (RBC) sedimentation for 20 minutes. The opaque supernatant was removed carefully without RBC contamination and placed on 15-ml Ficoll-paque (Amersham Biosciences, Piscataway, NJ, http://www.amersham.com) in a 50-ml tube (Falcon, BD Bioscience, Basel, Switzerland, http://www.bdbiosciences.com). Centrifugation (Sorvall RT6000D; rotor: H1000B) was performed at a relative centrifugal force (RCF) of 1600g for 20 minutes at 10¡ãC. The interface layer was placed into a new 50-ml tube, washed twice in phosphate-buffered saline (PBS), and counted afterwards. After an additional wash with PBS, cells were resuspended in culture medium (base medium) containing Dulbecco¡¯s modified Eagle¡¯s medium (DMEM)-F12 (Gibco, Grand Island, NY, http://www.invitrogen.com), 20% FCS (Socochim SA, Lausanne, Switzerland, http://www.socochim.ch), 100 IU/ml penicillin, and 100 µg/ml streptomycin (Sigma-Aldrich, St. Louis, http://www.sigmaaldrich.com). Cells were seeded at a density of 1.6 x 105 cells per cm2 and incubated in a humidified atmosphere at 37¡ãC with 5% CO2. Cultures were left for 2 weeks until the first medium exchange to allow cell attachment and to avoid cells becoming too densely packed in the growing cell colonies. The nonadherent floating cells were removed. Subsequently, medium was exchanged twice a week. Cells were reseeded into new flasks with 2.7 x 104 cells per cm2.; N3 ^" B6 D. z3 s& F3 z( n+ Y! H
% D2 B4 ]5 ~7 [7 g+ A
Equine bone marrow-derived MSCs were obtained from slaughtered horses immediately after stunning and bleeding. The samples were collected into syringes prepared with citric acid as described previously . The complete sample was placed on Ficoll-paque and processed according to the same protocol as described above for ePBPs. Unlike for ePBPs, the culture medium contained 10% FCS and was exchanged the first time 3 days after seeding.
* a7 I5 ~# ^0 e* j& }
Chondrogenic Differentiation

Expanded cells were harvested after three passages, washed in PBS, and resuspended in chondrogenic induction medium consisting of high-glucose DMEM (Gibco/Invitrogen AG, Basel, Switzerland, http://www.invitrogen.com), 0.275 µg/ml glucose (Sigma-Aldrich), 75 IU/ml penicillin, 75 µg/ml streptomycin, 10 µg/ml ITS  (Bioscience), 0.1 mM ascorbate-2-phosphate (Sigma-Aldrich), 10¨C7 M dexamethasone (Sigma-Aldrich), and 10 ng/ml human transforming growth factor (hTGF)-ß1 (DPC Biermann). ePBPs were resuspended in 4 ml of medium, placed in a 15-ml tube (Falcon), and spun down at an RCF of 300g to form a pellet consisting of 0.75 x 106 cells. Pellets were incubated for 2 weeks, and medium was exchanged twice a week .& u7 Z" }, O( |0 l. e. N! \

Osteogenic Differentiation) {  @* s9 i+ P( V

ePBPs were placed in a six-well plate (Nunc, Rochester, NY, http://www.nuncbrand.com) at a density of 50,000 cells per well in base medium for 24 hours to allow cell adhesion. Medium was replaced with osteogenic induction medium consisting of DMEM-F12, 10% FCS, 100 IU/ml penicillin, 100 µg/ml streptomycin, 10 mM ß-glycerophosphate, 10 nM dexamethasone, 0.1 mM ascorbate-2-phosphate (Sigma-Aldrich). Cells were cultured for 3 weeks in monolayer, and medium was exchanged twice a week .! Z' A! b& }3 }) W! e' U6 c* `
/ h, E: V0 O4 A8 c) p
Adipogenic Differentiation" M, ~2 u& Z1 j" L. d8 {
* o* s7 d; J3 X+ {8 z
Cells were seeded at the same density used in the osteogenic approach and cultured until confluence. Subsequently, cells were exposed to lipogenic induction medium consisting of base medium (10% FCS), 10 µg/ml insulin (Gibco), 1 µM dexamethasone, 100 µM indomethacin, and 500 µM 3-isobutyl-methyl-xanthine (Sigma-Aldrich) for 72 hours. Following this period, the medium was exchanged, and the cells were exposed to the adipogenic maintenance medium for the next 24 hours (one 96-hour cycle). This cycle of treatments was repeated four times in total, with an additional week in maintenance medium .. a' g5 v  T2 b3 X! r
9 |) W& W! v7 ^& p* S
Analysis Methods% k' a3 b2 a$ @2 P
; a1 U2 F' I4 O5 F2 J' C( I2 c
Gene Expression Analysis. Total RNA was isolated from equine PBPs and MSCs using the RNeasy kit (Qiagen, Hilden, Germany, http://www1.qiagen.com) and converted to cDNA with RevertAid H Minus M-MLV RT reverse transcriptase (Fermentas GmbH, St. Leon Rot, Germany, http://www.fermentas.com). To evaluate the amount of cDNA, conventional polymerase chain reaction (PCR) was performed with GAPDH primers (Microsynth, Balgach, Switzerland, http://www.microsynth.com) with the following sequences:
" l1 Y3 F; e% ~1 S8 t( l, z
Forward: ACATCAAGAAGGTGGTGAAG
8 M& ^1 [/ O* _
Reverse: ATTGTCGTACCAGGAAATGAG1 i' _& O9 j0 I/ x3 ?: N

To establish the expression levels of collagen type I and type II genes, real-time quantitative reverse transcription-polymerase chain reaction was performed and monitored using the ABI Prism 7700 Sequence Detection System (Applied BioSystems, Foster City, CA, http://www.appliedbiosystems.com). The polymerase chain reaction master mix was based on AmpliTaq Gold DNA polymerase (Applied BioSystems). Each cDNA sample (2.5 µl in a total volume of 25 µl per reaction) was analyzed separately and in duplicates. The gene of interest and the reference gene (18S ribosomal RNA) were labeled with 6-carboxylfluorescein. Primers and probes were purchased from Microsynth, and sequences and final concentrations used for human 18S, collagen type I, and collagen type II were as follows:

Collagen type I  I

Forward: CAGCCGCTTCACCTACAGC (300 nM)% [( g7 d3 C: E7 J" @( X
$ G( Y  \: l' A2 A. U: a
Reverse: TTTTGTATTCAATCACTGTCTTGCC (300 nM); g' k9 x8 s" A! D. r" N
) g3 [: a2 e; F4 Z, C9 P2 P4 `; _  L8 }
Probe: CCGGTGTGACTCGTGCAGCCATC (100 nM)2 D/ a# k, K6 f1 ]

Collagen type II  I3 i( z6 K. Q& v0 _: V, N* U

Forward: GGCAATAGCAGGTTCACGTACA (900 nM)
! B+ P0 ~7 w+ b$ p
Reverse: CGATAACAGTCTTGCCCCACTT (900 nM)
& w/ ]- L9 w# h- c* }! C2 n  k5 C
Probe: CCGGTATGTTTCGTGCAGCCATCCT (200 nM)- n, k' N5 n( X! _6 ]

18S

Forward: CGGCTACCACATCCAAGGAA (26 nM)
2 t8 K2 ?3 ~6 _0 ^
Reverse: GCTGGAATTACCGCGGCT(26 nM)" ~1 E; J7 ~, r- U- f5 W' \
3 {8 k4 N2 w4 g7 y
Probe: TGCTGGCACCAGACTTGCCCTC (50 nM)
* Y4 j  G* Q* |) q4 I  G; z- F. j( a
For each cDNA sample, the threshold cycle (Ct) value of each target sequence was subtracted from the Ct value of the reference gene to obtain the Ct. For each sample, the Ct value was determined as the cycle number at which the fluorescence intensity reached 0.05. The efficiencies of amplification for the chosen genes have been previously established for human primers and human cDNA samples . We have analyzed human primers amplification efficiency on horse cDNA and found no difference; for both species, the amplification efficiency depending on the primer ranged between 80% and 115%.

Histology. In the chondrogenic assay, the pellet cultures were embedded in paraffin and stained with safranin O, alcian blue, Masson trichrom, and hematoxylin and eosin. Immununohistochemistry (IHC) was performed for collagen types I and II. Primary antibodies were as follows: collagen I, Quartett catalog no. 031510101, lot no. 234214; collagen type II: Mo--Chicken II-II6B3, Developmental Studies Hybridoma Bank (University of Iowa, IA, http://www.uiowa.edu/~dshbwww/). Secondary antibodies were as follows: Go-a-Mo antibody Ig/Biotin, DAKO cytomation code no. E0433, lot no. 032(501) (DAKO, Glostrup, Denmark, http://www.dako.com).
+ d: N% T& \# ~7 \
In the osteogenic assay, cells were fixed and stained inside the six-well plates for alkaline phosphatase (kit 86C; Sigma-Aldrich). The cells of the adipogenic assay were also fixed inside the wells and stained with oil red O for the presence of lipid droplets .. A% U5 Z) |, h7 |# B
0 w. L- C4 P  ?% t" g) P
RESULTS5 f1 c# c" P. h

Blood samples from 33 different equine donors were processed. Twelve of 33 (36.4%) gave rise to fibroblast-like cells. After 14 days, 1¨C5 cell colonies were usually observed in the T75 culture flasks with a typical MSC fibroblast morphology (Fig. 1A). As a consequence of continued passaging, the cells changed to an elongated, spindle-like morphology with sharp borders (Fig. 1B). They stopped proliferation or grew in a side-by-side primary structure (Fig. 1C) and a net-shaped secondary structure (Fig. 1D). In all cases, proliferation activity decreased during passaging: in most samples, it was not possible to propagate the ePBPs beyond 5¨C6 passages. Importantly, the ePBPs proved very sensitive to trypsinization treatment. Extensive cell loss with a typical appearance of up to 50% floating cells 1 day after reseeding in a new culture flask was observed, suggesting that the protocol developed for bone marrow-derived MSCs is not optimal for ePBPs. It was possible to decrease cell loss during trypsin exposure, with strict optical control of cell detachment and immediate transfer to base medium. Another apparent loss of cells was observed after thawing ePBP samples stored in liquid nitrogen: whereas thawing bone marrow MSCs resulted in some floating cells after 24 hours (approximately 5%¨C10%), in ePBP cells, up to 50% were floating in the culture medium under similar conditions. The fragility of these cells may also be related to the initial culture conditions, where we allowed cell attachment for 2 weeks without medium changes.

Figure 1. Morphology of cultured equine peripheral blood-derived progenitors at different passages. (A): Isolated equine peripheral blood-derived progenitors (ePBPs) in P0 culture. This represents the typical morphology seen by day 14 following isolation. (B): Stretched-out ePBPs at the fifth passage. At this stage, cell proliferation ceased. (C): Typical fourth passage stretched-out cells proliferating in a side-by-side structure. (D): Cells proliferating in a side-by-side primary structure and a net-shaped secondary structure, also at passage 4. Magnifications x10.

In the chondrogenic induction, histology and IHC analysis show eMSC pellets stained positive for safranin O, alcian blue, and collagen type II but not for collagen type I (Fig. 2). Conversely, ePBP pellets did not display positive staining for any chondrogenic indicator, whereas collagen type I was detectable, suggesting a nondifferentiated phenotype (Fig. 2). To evaluate whether ePBPs required a longer time period to differentiate towards cartilage, pellet cultures from ePBPs were also maintained in induction medium for 3 weeks. No difference was observed in comparison with the 2-week-old neotissue at the histology and IHC level (Fig. 3). The cartilage-specific gene expression was assessed via the differentiation ratio of collagen type II to collagen type I . We observed a higher differentiation ratio in eMSC pellet cultures than in monolayer-cultured eMSCs (Fig. 4). Interestingly, we also noted the ratio increase in our control pellets that were not exposed to TGF-ß1. The absence of TGF-ß1 in ePBP pellet cultures displayed an increase of approximately 100-fold in the differentiation ratio compared with monolayer ePBPs. However, this was not observed in ePBP pellets incubated in the presence of TGF-ß1 (Fig. 4). The effect of TGF-ß1 is in agreement with other equine studies using MSCs and chondrocytes ongoing in our laboratory (data not shown).) @3 e1 P! P7 q1 Z9 Q% T
( Z  x/ n: Q* `  u5 p7 U
Figure 2. Chondrogenic induction. (A¨CD): Equine bone marrow-derived mesenchymal stem cell (MSCs). (E¨CH): Equine peripheral blood-derived progenitors (ePBPs). Histological staining included safranin O (A, E) and alcian blue (B, F). Immunohistochemistry used antibodies specific for collagen type II (C, G) and collagen type I (D, H). After 2 weeks of chondrogenic induction, equine MSCs showed a clear development of cartilage specific stainings, whereas ePBPs did not. Magnifications x40.4 X& \0 h7 Z3 L' d& p

Figure 3. Chondrogenic induction in equine peripheral blood-derived progenitors over 3 weeks. We hypothesized that a longer time in culture may yield a sign of chondrogenesis. However, as with the 2-week samples, we could not detect any positive indication of cartilage formation under the current conditions. (A): Safranin O staining. (B): Alcian blue staining. (C): Collagen type II immunohistochemistry. (D): Collagen type I immunohistochemistry. Magnifications x20.8 ]' q7 L1 e+ o+ G$ o
, @8 x+ H$ K8 E( H. Y
Figure 4. Cartilage formation was improved in pellet cultures from equine bone marrow and blood-derived MSCs when cultured in the absence of transforming growth factor-ß1 (TGF-ß1). The differentiation status of equine MSCs in monolayer and in pellet cultures was expressed as the ratio of collagen type II to collagen type I, the presence of collagen type II indicating the chondrocyte phenotype. Pellets were incubated for 3 weeks in medium with or without 10 ng/ml of TGF-ß1. Shown are typical collagen ratios obtained from bone marrow-derived MSCs (A) and blood-derived MSCs (B). Abbreviations: BM, bone marrow; MSCs, mesenchymal stem cells; PB, peripheral blood.& Q$ L2 ~5 u2 o5 k
/ {: w* {% R  y- v
In the osteogenic induction medium, the presence of alkaline phosphatase-positive cells was observed in all donors analyzed. The cells clearly altered their morphology toward more cubical shape with spike extensions and increased in size. In bone marrow samples, 82.5% ¡À 17.1% (mean ¡À SD; range, 60%¨C100%) of the cells were positive for alkaline phosphatase, compared with peripheral blood samples showing a large variation, ranging from 3%¨C100% (38.5% ¡À 39.1%). This divergence was not related to age because these extremes represented two 20-year-old Swiss warm-blooded horses. The negative controls kept in regular culture medium showed no change in their morphology, and very few cells stained positive for alkaline phosphatase (Fig. 5).

Figure 5. Osteogenic induction, alkaline phosphatase (AP) staining. After osteogenic induction, equine bone marrow and blood-derived mesenchymal stem cells (MSCs) showed strong staining for AP. Very few cells stained positive in the controls cultured in base medium. (A): AP-positive equine peripheral blood-derived progenitors (ePBPs). (B): AP-negative ePBPs kept in base culture medium as control. (C): APpositive equine MSCs. (D): AP-negative equine MSCs kept in base culture medium as control. Magnification x10.
2 E0 _2 J5 i7 i* A3 i9 a' S/ l
The adipogenic induction revealed a weak positive result in samples of eMSCs as well as in ePBPs as determined via oil red O staining (Fig. 6). Human MSCs showed much stronger lipid droplet development in parallel. Here, the ePBPs showed once more their increased sensitivity compared with MSCs. High cell detachment rates (cell death) and even confluent cell sheet detachment were observed in ePBPs exposed to adipogenic induction medium, whereas this phenomenon was limited in MSCs. In the negative controls kept in base culture medium, no lipid staining was detectable in either cell type.
# D7 M3 z5 a& k9 W
Figure 6. Adipogenic induction, oil red O staining. The equine cells from both cell sources developed very few lipid droplets. No droplets were found in the negative controls. (A): Equine mesenchymal stem cells. (B): equine peripheral blood-derived progenitors. Magnification x20./ k7 R3 i0 Q8 ?5 u4 a

DISCUSSION

In the current study, we have demonstrated the feasibility of isolating and propagating fibroblastoid cells from equine peripheral blood samples. In comparison with bone marrow-derived equine MSCs, where we could obtain adherent cells in all samples, we were successful in obtaining progenitors from only 36.4% of the donors. ePBPs appeared to reach senescence after passage 5 and developed an elongated morphology with sharp borders. The eMSCs appeared morphologically normal and did not show obvious signs of reduced proliferation capacity. It is possible that the isolation and propagation procedure of these cells may be improved by using specific substrates already described, such as fibronectin .$ ?) S" L: B6 B' N

The most striking finding in this study was the evidence of osteogenic differentiation in all ePBP samples. MSCs have been previously described for treatment of fracture sites to enhance bone healing . Clearly, use of ePBPs has immediate clinical implications as a minimally invasive treatment of such defects. To confirm the evidence of their osteogenic differentiation capacity, it will be useful to perform an in vivo assay as a proof of concept.

Another conspicuous finding was the response of equine cells to TGF-ß1 in the chondrogenic assays. It was evident that eMSCs formed cartilage with and without the presence of TGF-ß1, which is in contrast with human cells that require this morphogen to induce chondrogenesis . Although we did not find convincing evidence of cartilage formation using histology and immunostaining in ePBP pellet cultures, there is a suggestion at the gene expression level that these blood-derived cells may have the potential to produce cartilage. Further refinement of in vitro conditions and an eventual in vivo implantation model may concur with this notion.

The isolation and propagation of peripheral blood-derived fibroblastoid cells from adults is challenging. In human . This raises the question of whether these are true progenitors or whether the definition of self-renewal is really an inclusive trait of all progenitor cells.% i4 @! W- B" r* ^

Researchers who worked with human peripheral blood as a stem cell source were content with finding evidence of human mesenchymal markers such as CD105, SH2, or SH3 in their primary culture of fibroblastoid cells without testing the differentiation capacity , have proven to be good induction factors to promote chondrogenesis in equine MSCs. In all, it is obvious that in vitro conditions currently provided need further modification to reliably allow cartilage differentiation from each cell type and species.- v8 `, g* M; W+ Q
0 w4 i2 C% e2 e! J
In the same theme as discussed above, limited adipogenesis in both cell types (i.e., ePBPs and eMSCs) may depend on the induction medium, since the methods used here were designed for human bone marrow-derived MSCs. To the best of our knowledge, there are no protocols available for a horse-specific adipogenesis of progenitor cells, and this is likely due to the limited clinical use of adipocytes in this species in contrast to bone and cartilage.
6 N/ Z+ o  I5 N$ C# e
These results show once again the difficulties of obtaining mesenchymal progenitors from peripheral blood. Nevertheless, since equine PBPs are easier to isolate than human PBPs (data not shown) and the horse represents a very good model for clinical stem cell research, it is very important to evaluate their differentiation abilities. These cells may have no value for cartilage engineering but for the clinical application in bone, tendon, and ligament defects. Furthermore, peripheral blood could represent a safer source to avoid possible complications associated with harvesting bone marrow aspirates.
2 i  R0 v5 ~; E$ X: m3 p
Future studies should aim at improving primary isolation techniques to increase the success rate in obtaining adherent fibroblastoid cells. Further optimization of proliferation and differentiation conditions would bring cell-based therapies for horses to a clinical level. Since the appearance of ePBPs in the mononuclear cell fraction is very low, work should focus on obtaining higher amounts of these cells. One possibility may be via elutriation, as previously described in humans .. ^3 n9 B8 P) d3 A5 a, W6 `1 |; U

CONCLUSION# x( F* E$ ^, _" I
" }( T1 R. n  L* \8 m' A" K% e, P
The advantage of peripheral blood-derived progenitors is the simplicity of obtaining cells in a safe and virtually pain-free way for the patient. On the other hand, PBPs are very fragile and have limited expansion capacity, which presents a problem if a high number of cells are needed. The differentiation capacity of ePBPs toward bone and fat demonstrated individual variation and was somewhat comparable with eMSCs and hMSCs. However, no differentiation toward cartilage at the histological level was obvious. Peripheral blood-derived progenitors do show capacity of multi lineage differentiation potential, albeit limited. Until proven otherwise, the bone marrow currently represents the most valuable and reliable progenitor source for tissue engineering and reconstructive therapies in the horse and other species.3 G0 B) u. v$ A- Y

DISCLOSURES
. |5 j8 q8 V* g. B0 d
The authors indicate no potential conflicts of interest.6 R; _5 y) W" L8 Y9 r! q
3 ^2 \. {) S' j( S4 {
ACKNOWLEDGMENTS

S.P.G. is currently affiliated with The Scripps Research Institute, Division of Arthritis Research, MEM-161, La Jolla, CA. Special acknowledgment is due to Verena Winkelmann and Chantal Pauli for the preparation of the histology and immunohistochemistry. This work was supported by the AO Research Fund, D¨¹bendorf, Switzerland (grant 04-B1) and the Holcim Stiftung zur Förderung wissenschaftlicher Fortbildung, Holderbank, Switzerland (to S.P.G.).
      【参考文献】7 Z/ `6 Z9 ^- v) Y
" I. o+ Q8 d% D, S1 ^; @

Huss R. Isolation of primary and immortalized CD34-hematopoietic and mesenchymal stem cells from various sources. STEM CELLS 2000;18: 1¨C9.

Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate MSC-like cells from umbilical cord. STEM CELLS 2003;21:105¨C110.$ n0 ]7 o# w6 y: h

Covas DT, Siufi JL, Silva AR et al. Isolation and culture of umbilical vein mesenchymal stem cells. Braz J Med Biol Res 2003;36:1179¨C1183.
* o& E' e1 G, q2 m, A+ {4 K4 K7 ]
Wickham MQ, Erickson GR, Gimble JM et al. Multipotent stromal cells derived from the infrapatellar fat pad of the knee. Clin Orthop 2003;412: 196¨C212.% J7 V% I; e2 O. H

Zuk PA, Zhu M, Mizuno H et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 2001;7:211¨C228.3 H3 e+ Y1 k5 l8 Z$ V6 `
* z; r8 D1 g' w" k8 @% Z
Williams JT, Southerland SS, Souza J et al. Cells isolated from adult human skeletal muscle capable of differentiating into multiple mesodermal phenotypes. Am Surg 1999;65:22¨C26.
+ _, h! c1 Z0 f. i! S, k
Vescovi AL, Galli R, Gritti A. The neural stem cells and their transdifferentiation capacity. Biomed Pharmacother 2001;55:201¨C205.

De Bari C, Dell¡¯Accio F, Tylzanowski P et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001; 44:1928¨C1942.
' e, r$ C$ q1 X! S( ?& R
Noth U, Osyczka AM, Tuli R et al. Multilineage mesenchymal differentiation potential of human trabecular bone-derived cells. J Orthop Res 2002;20:1060¨C1069.

Sottile V, Halleux C, Bassilana F et al. Stem cell characteristics of human trabecular bone-derived cells. Bone 2002;30:699¨C704.
, P: X9 c- |3 `' [; y1 B4 b
Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: In vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet 1987;20:263¨C272.4 M8 L: f. _; v5 v# z0 p9 i  z
( L1 V: _+ i+ [! a5 Y2 J: }
Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000;113:1161¨C1166.
% I7 n* Y- Q, i
Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143¨C147./ [/ s3 y  M- D, ~/ U" b. y
, O# h% X1 |* z7 `7 h  }2 n' k' `
Zvaifler NJ, Marinova-Mutafchieva L, Adams G et al. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res 2000;2: 477¨C488.

Kuwana M, Okazaki Y, Kodama H et al. Human circulating CD14  monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 2003;74:833¨C845.
( o8 J; m9 g+ B! e- Z) a" d+ S; v
Fortier LA, Nixon AJ, Williams J et al. Isolation and chondrocytic differentiation of equine bone marrow-derived mesenchymal stem cells. Am J Vet Res 1998;59:1182¨C1187.
( B/ s: q# ^& C- i
Smith RK, Korda M, Blunn GW et al. Isolation and implantation of autologous equine mesenchymal stem cells from bone marrow into the superficial digital flexor tendon as a potential novel treatment. Equine Vet J 2003;35:99¨C102.

Hegewald AA, Ringe J, Bartel J et al. Hyaluronic acid and autologous synovial fluid induce chondrogenic differentiation of equine mesenchymal stem cells: A preliminary study. Tissue Cell 2004;36:431¨C438.

Pittenger MF, Mosca JD, McIntosh KR. Human mesenchymal stem cells: Progenitor cells for cartilage, bone, fat and stroma. Curr Top Microbiol Immunol 2000;251:3¨C11.' `+ {* {2 Q5 l* D( ~1 l' m  }( m

Roufosse CA, Direkze NC, Otto WR et al. Circulating mesenchymal stem cells. Int J Biochem Cell Biol 2004;36:585¨C597.
; x: {9 d1 ^9 R" A6 [; h3 Z6 w
Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000;109:235¨C242.! g: `2 b8 p. u4 u3 u# M7 g- O

Campagnoli C, Roberts IA, Kumar S et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001;98:2396¨C2402.
3 |8 O- U1 \1 M" v& {
Yu M, Xiao Z, Shen L et al. Mid-trimester fetal blood-derived adherent cells share characteristics similar to mesenchymal stem cells but full-term umbilical cord blood does not. Br J Haematol 2004;124:666¨C675.. w# P# G& j. p) P

Lee OK, Kuo TK, Chen WM et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004;103:1669¨C1675.
2 W$ J# ]5 W0 H  y8 j* S9 j
Bieback K, Kern S, Kluter H et al. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. STEM CELLS 2004;22:625¨C634.  B9 F/ f! ]# ?' A3 ^0 Y. {, G8 J
, f% k: Y' f* O9 D( i4 D5 D/ g2 l4 g
Goodwin HS, Bicknese AR, Chien SN et al. Multilineage differentiation activity by cells isolated from umbilical cord blood: Expression of bone, fat, and neural markers. Biol Blood Marrow Transplant 2001;7:581¨C588.
; p4 E5 g  |9 `5 A2 \( m+ r) p; N
Wexler SA, Donaldson C, Denning-Kendall P et al. Adult bone marrow is a rich source of human mesenchymal ¡®stem¡¯ cells but umbilical cord and mobilized adult blood are not. Br J Haematol 2003;121:368¨C374.
" W# z" x! j0 W0 x% W
Lazarus HM, Haynesworth SE, Gerson SL et al. Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections. J Hematother 1997;6:447¨C455.
: m1 S% i5 S3 s) Z
Fernandez M, Simon V, Herrera G et al. Detection of stromal cells in peripheral blood progenitor cell collections from breast cancer patients. Bone Marrow Transplant 1997;20:265¨C271.
8 ^! W& I0 O# n" L1 _
Conrad C, Gottgens B, Kinston S et al. GATA transcription in a small rhodamine 123(low)CD34( ) subpopulation of a peripheral blood-derived CD34(¨C)CD105( ) mesenchymal cell line. Exp Hematol 2002; 30:887¨C895.

Kuznetsov SA, Mankani MH, Gronthos S et al. Circulating skeletal stem cells. J Cell Biol 2001;153:1133¨C1140.  \. m3 e. L4 v' H5 k
$ M8 v- T  y9 r  r! [
Zhao Y, Glesne D, Huberman E. A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc Natl Acad Sci U S A 2003;100:2426¨C2431.0 `+ F( t* X) g7 b# y( w

Huss R, Lange C, Weissinger EM et al. Evidence of peripheral blood-derived, plastic-adherent CD34(¨C/low) hematopoietic stem cell clones with mesenchymal stem cell characteristics. STEM CELLS 2000;18:252¨C260.
1 X* d; }6 C* j* S9 d. S! R; h0 D# W
Caplan AI, Bruder SP. Mesenchymal stem cells: Building blocks for molecular medicine in the 21st century. Trends Mol Med 2001;7:259¨C264.

Barry FP, Murphy JM. Mesenchymal stem cells: Clinical applications and biological characterization. Int J Biochem Cell Biol 2004;36:568¨C584.; X& G4 W& Y9 ]3 a
4 V4 E, m! K8 q4 K
Naumann A, Dennis J, Staudenmaier R et al." B4 O: d) k) A1 z- l2 U3 L
4 V* |* t4 p0 i/ t1 \
Murphy JM, Fink DJ, Hunziker EB et al. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003;48:3464¨C3474.) {& `. V/ x$ r) R# C, c' K. c
; g! v2 z+ ]' L' H) [; R/ R7 {
Arnoczky SP. Building a meniscus. Biologic considerations. Clin Orthop 1999;367(suppl):S244¨CS253.9 t) i2 L" M* K2 q3 Z6 r, `' X

Caplan AI. The mesengenic process. Clin Plast Surg 1994;21:429¨C435.- v, P9 v0 K1 a
9 w( N2 g2 W: L
Mackay AM, Beck SC, Murphy JM et al. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 1998;4:415¨C428.; T' ^1 d# Y, X$ n& l
+ a* r+ e1 H( b. k
Barbero A, Ploegert S, Heberer M et al. Plasticity of clonal populations of dedifferentiated adult human articular chondrocytes. Arthritis Rheum 2003;48:1315¨C1325.8 @4 y, i+ x( y/ M3 k5 @6 A" z

Jaiswal RK, Jaiswal N, Bruder SP et al. Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. J Biol Chem 2000;275:9645¨C9652.
" w1 ~* I2 @" E2 p
Janderova L, McNeil M, Murrell AN et al. Human mesenchymal stem cells as an in vitro model for human adipogenesis. Obes Res 2003;11: 65¨C74.
( p  }# c: Q2 d$ V  H! v
Diaz-Romero J, Gaillard JP, Grogan SP et al. Immunophenotypic analysis of human articular chondrocytes: Changes in surface markers associated with cell expansion in monolayer culture. J Cell Physiol 2005; 202:731¨C742.

Martin I, Jakob M, Schafer D et al. Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints. Osteoarthritis Cartilage 2001;9:112¨C118.

Yamada Y, Ueda M, Naiki T et al. Autogenous injectable bone for regeneration with mesenchymal stem cells and platelet-rich plasma: Tissue-engineered bone regeneration. Tissue Eng 10:955¨C964, 2004.0 F1 }) V* ~8 Q  d! z; @, s4 o! j

Lee K, Majumdar MK, Buyaner D et al. Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther 2001;3:857¨C866.
0 q  A6 E+ ?2 W  I/ }6 @
Worster AA, Brower-Toland BD, Fortier LA et al. Chondrocytic differentiation of mesenchymal stem cells sequentially exposed to transforming growth factor-beta1 in monolayer and insulin-like growth factor-I in a three-dimensional matrix. J Orthop Res 2001;19:738¨C749.* ?4 C: m9 X) d9 q% z

Angele P, Schumann D, Angele M et al. Cyclic, mechanical compression enhances chondrogenesis of mesenchymal progenitor cells in tissue engineering scaffolds. Biorheology 41:335¨C346, 2004.
1 h$ l) ?6 Q9 C2 r
Angele P, Yoo JU, Smith C et al. Cyclic hydrostatic pressure enhances the chondrogenic phenotype of human mesenchymal progenitor cells differentiated in vitro. J Orthop Res 2003;21:451¨C457.: Z1 p1 z: m/ }. z. B& s

Barry F, Boynton RE, Liu B et al. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: Differentiation-dependent gene expression of matrix components. Exp Cell Res 2001;268:189¨C200.

收藏0 分享0 顶0 踩0